Key result
Lipid testing in hospital was associated with higher rates of initiation or escalation of statin therapy within 90 days of incident ACS (adjusted OR 2.13; 95% CI 1.97-2.30).
Why the study?
PCSK9 inhibitor eligibility had not been studied in a large population-based post-ACS cohort.
Cohort (n=27,979)
Yes
Odds Ratio: 2.13 (95% CI 1.97–2.3)
A large proportion of post-ACS patients do not meet guideline-recommended lipid thresholds, and nearly 40% of tested patients would be eligible for PCSK9i therapy, highlighting a significant gap in secondary prevention.
No takes yet. Share an insight, caveat, or question.
Supports routine inpatient lipid assessment to close secondary prevention gaps post-ACS; leaves open whether this.
Sarak et al. (2021) conducted a cohort in Incident Acute Coronary Syndrome (n=27,979). Lipid testing in hospital vs. No lipid testing in hospital was evaluated on Initiation or escalation of statin therapy within 90 days of ACS (adjusted OR 2.13, 95% CI 1.97-2.30). Lipid testing in hospital was associated with higher rates of initiation or escalation of statin therapy within 90 days of incident ACS (adjusted OR 2.13; 95% CI 1.97-2.30).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: